Parathyroidectomy rates among United States dialysis patients: 1990-1999

Kidney International

Volumn 65, Issue 1, 2004, Pages 282-288

  Kestenbaum, Bryan ^a   Seliger, Stephen L ^b   Gillen, Daniel L ^b   Wasse, Haimanot ^b   Young, Bessie ^b   Sherrard, Donald J ^b   Weiss, Noel S ^b   Stehman Breen, Catherine O ^b  

^a Division of Nephrology   (United States)

^b NONE

Author keywords

Diabetes; Dialysis; Incidence; Parathyroidectomy; Rates

Indexed keywords

PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIALYSIS; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; PATIENT CODING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SEX DIFFERENCE; STATISTICAL ANALYSIS; UNITED STATES;

EID: 0346732040     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00368.x     Document Type: Article

References (34)

1. SHERRARD DJ, HERCZ G, PEI Y, et al: The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int 43:436-442, 1993
2. SHERRARD D, BAYLINK D, WERGEDAL J: Bone disease in uremia. Trans Am Soc Artif Intern Organs 18:412-415, 1972
3. PEI Y, HERCZ G, GREENWOOD C, et al: Risk factors for renal osteodystrophy: A multivariant analysis. J Bone Miner Res 10:149-156, 1995
4. BLOCK GA, HULBERT-SHEARON TE, LEVIN NW, et al: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
5. GANESH SK, STACK AG, LEVIN NW, et al: Association of elevated serum PO(4). Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
6. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
7. DELMEZ JA, TINDIRA CA, WINDUS DW, et al: Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 3:96-102, 1992
8. ANDRESS DL, NORRIS KC, COBURN JW, et al: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
9. CHERTOW GM, BURKE SK, LAZARUS JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
10. MALBERTI F, MARCELLI D, CONTE F, et al: Parathyroidectomy in patients on renal replacement therapy: An epidemiologic study. J Am Soc Nephrol 12:1242-1248, 2001
11. HERCZ G, PEI Y, GREENWOOD C, et al: Aplastic osteodystrophy without aluminum: the role of "suppressed" parathyroid function. Kidney Int 44:860-866, 1993
12. USRDS: Researche's Guide to the USRDS Database. Bethesda, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
13. MCCULLACH P, NELDER JA: Generalized Linear Models, 2nd ed., London (U.K.), Chapman and Hall, 1989
14. WING AJ, BROYER M, BRUNNER FP, et al: Combined report on regular dialysis and transplantation in Europe, XIII, 1982. Proc Eur Dial Transplant Assoc 20:2-75, 1983
15. TOKUYAMA K, ISEKI K, YOSHI S, et al: An epidemiologic analysis of parathyroidectomy in chronic dialysis patients. The Okinawa Dialysis Study Group. Nippon Jinzo Gakkai Shi 38:309-313, 1996
16. FASSBINDER W, BRUNNER FP, BRYNGER H, et al: Combined report on regular dialysis and transplantation in Europe, XX, 1989. Nephrol Dial Transplant 6(Suppl 1):5-35, 1991
17. MARTIN KJ, GONZALEZ EA: Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 38:S34-40, 2001
18. CHERTOW GM, BURKE SK, DILLON MA, et al: Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 15:559, 2000
19. PUNCH JD, THOMPSON NW, MERION RM: Subtotal parathyroidectomy in dialysis-dependent and post-renal transplant patients. A 25-year single-center experience. Arch Surg 130:538-542
20. CHOU FF, HO JC, HUANG SC, et al: A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg 190:65-70, 2000
21. BRO S, OLGAARD K: Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 30:606-620, 1997
22. AMANN K, RITZ E, WIEST G, et al: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814-1819, 1994
23. MALLUCHE HH, MONIER-FAUGERE MC: Risk of adynamic bone disease in dialyzed patients. Kidney Int (Suppl 38):S62-67, 1992
24. MARTINEZ I, SARACHO R, MOINA I, et al: Is there a lesser hyperparathyroidism in diabetic patients with chronic renal failure? Nephrol Dial Transplant 13(Suppl 3):9-11, 1998
25. PEI Y, HERCZ G, GREENWOOD C, et al: Renal osteodystrophy in diabetic patients. Kidney Int 44:159-164, 1993
26. YAMAMOTO T, OZONO K, MIYAUCHI A, et al: Role of advanced glycation end products in adynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 38:S161-164, 2001
27. PANUCCIO V, MALLAMACI F, TRIPEPI G, et al: Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis 40:810-815, 2002
28. SUGIMOTO T, RITTER C, MORRISSEY J, et al: Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 37:1522-1527, 1990
29. KLAHR S, LEVEY AS, BECK GJ, et al: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884, 1994
30. COUTTENYE MM, D'HAESE PC, DENG JT, et al: High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 12:2144-2150, 1997
31. JOHNSON CA, MCCARTHY J, BAILIE GR, et al: Analysis of renal bone disease treatment in dialysis patients. Am J Kidney Dis 39:1270-1277, 2002
32. MELTON LJ, 3RD: The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 17(Suppl 2):N12-17, 2002
33. GUPTA A, KALLENBACH LR, ZASUWA G, et al: Race is a major determinant of secondary hyperparathyroidism in uremic patients. J Am Soc Nephrol 11:330-334, 2000
34. PRINCE RL: Counterpoint: estrogen effects on calcitropic hormones and calcium homeostasis. Endocr Rev 15:301-309, 1994